BEAM Autografting in Lymphoma-Experience at One Centre
Since December 1987, we have examined the use of high-dose chemotherapy and unpurged bone marrow rescue in 31 patients with advanced or refractory lymphoma. Twenty-one patients had Hodgkin's disease (HD) and 10 had Non-Hodgkin's lymphoma (NHL). At ABMT, 22 patients had relapsed or resistan...
Gespeichert in:
| Veröffentlicht in: | Leukemia & lymphoma 1992, Vol.7 (S1), p.23-28 |
|---|---|
| Hauptverfasser: | , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 28 |
|---|---|
| container_issue | S1 |
| container_start_page | 23 |
| container_title | Leukemia & lymphoma |
| container_volume | 7 |
| creator | Smith, Adrian G. Long, Simon G. Janmohammed, Riaz M. I. Macdonald, Dorothy F. Leyland, Michael J. Milligan, Donald W. |
| description | Since December 1987, we have examined the use of high-dose chemotherapy and unpurged bone marrow rescue in 31 patients with advanced or refractory lymphoma. Twenty-one patients had Hodgkin's disease (HD) and 10 had Non-Hodgkin's lymphoma (NHL). At ABMT, 22 patients had relapsed or resistant disease. All patients, excluding 3 early deaths, engrafted. There was no relationship between cell numbers harvested, CFU-GM and bone marrow recovery. The mean times to 0.5 × 109/1 neutrophils and 50 × 109/1 platelets were 20 d and 43 d respectively. However, 5 patients with HD had a significantly slower platelet recovery time of up to 203 days (p = 0.05). Disease-free survival was 72% for HD and 40% for NHL at 40 months. Relapsed or refractory disease at ABMT, bulky disease, extensive salvage therapy and Karnofsky scores below 80% were all associated with a poorer outcome. The most striking observation has been the dramatic radiological response of some patients with advanced/refractory disease. |
| doi_str_mv | 10.3109/10428199209061560 |
| format | Article |
| fullrecord | <record><control><sourceid>informahealthcare_cross</sourceid><recordid>TN_cdi_crossref_primary_10_3109_10428199209061560</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>10_3109_10428199209061560</sourcerecordid><originalsourceid>FETCH-LOGICAL-c401t-6c23641c6a063397e5bd862e1b20678441b52b2ce976e723ffdc35406723cbb3</originalsourceid><addsrcrecordid>eNp9kN1Kw0AQhRdRaq0-gBdCXiA6-5suelNL_YFKb3ofNptJm5Lshk2K9u1NiSAiejUDZ77DnEPINYVbTkHfURBsSrVmoEFRqeCEjCkwHTMB_PS4Cxb3B-KcXLTtDgCkVmxERlRoLqQcE_W4mL1Fs33nN8EUXek2Uemi5aFutr428eKjwVCisxiZLlo5jObouoCX5KwwVYtXX3NC1k-L9fwlXq6eX-ezZWwF0C5WlnElqFUGFOc6QZnlU8WQZgxUMhWCZpJlzKJOFCaMF0VuuRS9xrjNMj4hdLC1wbdtwCJtQlmbcEgppMcG0l8N9MzNwDT7rMb8mxgi9_rDoJeu8KE27z5UedqZQ-VDEYyzZXu0_tv-_ge-RVN1W2sCpju_D65v45_nPgE_jnkF</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>BEAM Autografting in Lymphoma-Experience at One Centre</title><source>MEDLINE</source><source>Taylor & Francis Medical Library - CRKN</source><source>Taylor & Francis Journals Complete</source><creator>Smith, Adrian G. ; Long, Simon G. ; Janmohammed, Riaz M. I. ; Macdonald, Dorothy F. ; Leyland, Michael J. ; Milligan, Donald W.</creator><creatorcontrib>Smith, Adrian G. ; Long, Simon G. ; Janmohammed, Riaz M. I. ; Macdonald, Dorothy F. ; Leyland, Michael J. ; Milligan, Donald W.</creatorcontrib><description>Since December 1987, we have examined the use of high-dose chemotherapy and unpurged bone marrow rescue in 31 patients with advanced or refractory lymphoma. Twenty-one patients had Hodgkin's disease (HD) and 10 had Non-Hodgkin's lymphoma (NHL). At ABMT, 22 patients had relapsed or resistant disease. All patients, excluding 3 early deaths, engrafted. There was no relationship between cell numbers harvested, CFU-GM and bone marrow recovery. The mean times to 0.5 × 109/1 neutrophils and 50 × 109/1 platelets were 20 d and 43 d respectively. However, 5 patients with HD had a significantly slower platelet recovery time of up to 203 days (p = 0.05). Disease-free survival was 72% for HD and 40% for NHL at 40 months. Relapsed or refractory disease at ABMT, bulky disease, extensive salvage therapy and Karnofsky scores below 80% were all associated with a poorer outcome. The most striking observation has been the dramatic radiological response of some patients with advanced/refractory disease.</description><identifier>ISSN: 1042-8194</identifier><identifier>EISSN: 1029-2403</identifier><identifier>DOI: 10.3109/10428199209061560</identifier><identifier>PMID: 1493455</identifier><language>eng</language><publisher>United States: Informa UK Ltd</publisher><subject>Adolescent ; Adult ; Antineoplastic Combined Chemotherapy Protocols - adverse effects ; Antineoplastic Combined Chemotherapy Protocols - therapeutic use ; Bone Marrow Transplantation ; Carmustine - adverse effects ; Carmustine - therapeutic use ; Combined Modality Therapy ; Cytarabine - adverse effects ; Cytarabine - therapeutic use ; Etoposide - adverse effects ; Etoposide - therapeutic use ; Female ; Humans ; lymphoma ; Lymphoma - mortality ; Lymphoma - therapy ; Male ; Melphalan - adverse effects ; Melphalan - therapeutic use ; Middle Aged ; Survival Rate ; Transplantation, Autologous</subject><ispartof>Leukemia & lymphoma, 1992, Vol.7 (S1), p.23-28</ispartof><rights>1992 Informa UK Ltd All rights reserved: reproduction in whole or part not permitted 1992</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c401t-6c23641c6a063397e5bd862e1b20678441b52b2ce976e723ffdc35406723cbb3</citedby><cites>FETCH-LOGICAL-c401t-6c23641c6a063397e5bd862e1b20678441b52b2ce976e723ffdc35406723cbb3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.tandfonline.com/doi/pdf/10.3109/10428199209061560$$EPDF$$P50$$Ginformahealthcare$$H</linktopdf><linktohtml>$$Uhttps://www.tandfonline.com/doi/full/10.3109/10428199209061560$$EHTML$$P50$$Ginformahealthcare$$H</linktohtml><link.rule.ids>314,777,781,4010,27904,27905,27906,59626,59732,60415,60521,61200,61235,61381,61416</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/1493455$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Smith, Adrian G.</creatorcontrib><creatorcontrib>Long, Simon G.</creatorcontrib><creatorcontrib>Janmohammed, Riaz M. I.</creatorcontrib><creatorcontrib>Macdonald, Dorothy F.</creatorcontrib><creatorcontrib>Leyland, Michael J.</creatorcontrib><creatorcontrib>Milligan, Donald W.</creatorcontrib><title>BEAM Autografting in Lymphoma-Experience at One Centre</title><title>Leukemia & lymphoma</title><addtitle>Leuk Lymphoma</addtitle><description>Since December 1987, we have examined the use of high-dose chemotherapy and unpurged bone marrow rescue in 31 patients with advanced or refractory lymphoma. Twenty-one patients had Hodgkin's disease (HD) and 10 had Non-Hodgkin's lymphoma (NHL). At ABMT, 22 patients had relapsed or resistant disease. All patients, excluding 3 early deaths, engrafted. There was no relationship between cell numbers harvested, CFU-GM and bone marrow recovery. The mean times to 0.5 × 109/1 neutrophils and 50 × 109/1 platelets were 20 d and 43 d respectively. However, 5 patients with HD had a significantly slower platelet recovery time of up to 203 days (p = 0.05). Disease-free survival was 72% for HD and 40% for NHL at 40 months. Relapsed or refractory disease at ABMT, bulky disease, extensive salvage therapy and Karnofsky scores below 80% were all associated with a poorer outcome. The most striking observation has been the dramatic radiological response of some patients with advanced/refractory disease.</description><subject>Adolescent</subject><subject>Adult</subject><subject>Antineoplastic Combined Chemotherapy Protocols - adverse effects</subject><subject>Antineoplastic Combined Chemotherapy Protocols - therapeutic use</subject><subject>Bone Marrow Transplantation</subject><subject>Carmustine - adverse effects</subject><subject>Carmustine - therapeutic use</subject><subject>Combined Modality Therapy</subject><subject>Cytarabine - adverse effects</subject><subject>Cytarabine - therapeutic use</subject><subject>Etoposide - adverse effects</subject><subject>Etoposide - therapeutic use</subject><subject>Female</subject><subject>Humans</subject><subject>lymphoma</subject><subject>Lymphoma - mortality</subject><subject>Lymphoma - therapy</subject><subject>Male</subject><subject>Melphalan - adverse effects</subject><subject>Melphalan - therapeutic use</subject><subject>Middle Aged</subject><subject>Survival Rate</subject><subject>Transplantation, Autologous</subject><issn>1042-8194</issn><issn>1029-2403</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>1992</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp9kN1Kw0AQhRdRaq0-gBdCXiA6-5suelNL_YFKb3ofNptJm5Lshk2K9u1NiSAiejUDZ77DnEPINYVbTkHfURBsSrVmoEFRqeCEjCkwHTMB_PS4Cxb3B-KcXLTtDgCkVmxERlRoLqQcE_W4mL1Fs33nN8EUXek2Uemi5aFutr428eKjwVCisxiZLlo5jObouoCX5KwwVYtXX3NC1k-L9fwlXq6eX-ezZWwF0C5WlnElqFUGFOc6QZnlU8WQZgxUMhWCZpJlzKJOFCaMF0VuuRS9xrjNMj4hdLC1wbdtwCJtQlmbcEgppMcG0l8N9MzNwDT7rMb8mxgi9_rDoJeu8KE27z5UedqZQ-VDEYyzZXu0_tv-_ge-RVN1W2sCpju_D65v45_nPgE_jnkF</recordid><startdate>1992</startdate><enddate>1992</enddate><creator>Smith, Adrian G.</creator><creator>Long, Simon G.</creator><creator>Janmohammed, Riaz M. I.</creator><creator>Macdonald, Dorothy F.</creator><creator>Leyland, Michael J.</creator><creator>Milligan, Donald W.</creator><general>Informa UK Ltd</general><general>Taylor & Francis</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope></search><sort><creationdate>1992</creationdate><title>BEAM Autografting in Lymphoma-Experience at One Centre</title><author>Smith, Adrian G. ; Long, Simon G. ; Janmohammed, Riaz M. I. ; Macdonald, Dorothy F. ; Leyland, Michael J. ; Milligan, Donald W.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c401t-6c23641c6a063397e5bd862e1b20678441b52b2ce976e723ffdc35406723cbb3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>1992</creationdate><topic>Adolescent</topic><topic>Adult</topic><topic>Antineoplastic Combined Chemotherapy Protocols - adverse effects</topic><topic>Antineoplastic Combined Chemotherapy Protocols - therapeutic use</topic><topic>Bone Marrow Transplantation</topic><topic>Carmustine - adverse effects</topic><topic>Carmustine - therapeutic use</topic><topic>Combined Modality Therapy</topic><topic>Cytarabine - adverse effects</topic><topic>Cytarabine - therapeutic use</topic><topic>Etoposide - adverse effects</topic><topic>Etoposide - therapeutic use</topic><topic>Female</topic><topic>Humans</topic><topic>lymphoma</topic><topic>Lymphoma - mortality</topic><topic>Lymphoma - therapy</topic><topic>Male</topic><topic>Melphalan - adverse effects</topic><topic>Melphalan - therapeutic use</topic><topic>Middle Aged</topic><topic>Survival Rate</topic><topic>Transplantation, Autologous</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Smith, Adrian G.</creatorcontrib><creatorcontrib>Long, Simon G.</creatorcontrib><creatorcontrib>Janmohammed, Riaz M. I.</creatorcontrib><creatorcontrib>Macdonald, Dorothy F.</creatorcontrib><creatorcontrib>Leyland, Michael J.</creatorcontrib><creatorcontrib>Milligan, Donald W.</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><jtitle>Leukemia & lymphoma</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Smith, Adrian G.</au><au>Long, Simon G.</au><au>Janmohammed, Riaz M. I.</au><au>Macdonald, Dorothy F.</au><au>Leyland, Michael J.</au><au>Milligan, Donald W.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>BEAM Autografting in Lymphoma-Experience at One Centre</atitle><jtitle>Leukemia & lymphoma</jtitle><addtitle>Leuk Lymphoma</addtitle><date>1992</date><risdate>1992</risdate><volume>7</volume><issue>S1</issue><spage>23</spage><epage>28</epage><pages>23-28</pages><issn>1042-8194</issn><eissn>1029-2403</eissn><abstract>Since December 1987, we have examined the use of high-dose chemotherapy and unpurged bone marrow rescue in 31 patients with advanced or refractory lymphoma. Twenty-one patients had Hodgkin's disease (HD) and 10 had Non-Hodgkin's lymphoma (NHL). At ABMT, 22 patients had relapsed or resistant disease. All patients, excluding 3 early deaths, engrafted. There was no relationship between cell numbers harvested, CFU-GM and bone marrow recovery. The mean times to 0.5 × 109/1 neutrophils and 50 × 109/1 platelets were 20 d and 43 d respectively. However, 5 patients with HD had a significantly slower platelet recovery time of up to 203 days (p = 0.05). Disease-free survival was 72% for HD and 40% for NHL at 40 months. Relapsed or refractory disease at ABMT, bulky disease, extensive salvage therapy and Karnofsky scores below 80% were all associated with a poorer outcome. The most striking observation has been the dramatic radiological response of some patients with advanced/refractory disease.</abstract><cop>United States</cop><pub>Informa UK Ltd</pub><pmid>1493455</pmid><doi>10.3109/10428199209061560</doi><tpages>6</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1042-8194 |
| ispartof | Leukemia & lymphoma, 1992, Vol.7 (S1), p.23-28 |
| issn | 1042-8194 1029-2403 |
| language | eng |
| recordid | cdi_crossref_primary_10_3109_10428199209061560 |
| source | MEDLINE; Taylor & Francis Medical Library - CRKN; Taylor & Francis Journals Complete |
| subjects | Adolescent Adult Antineoplastic Combined Chemotherapy Protocols - adverse effects Antineoplastic Combined Chemotherapy Protocols - therapeutic use Bone Marrow Transplantation Carmustine - adverse effects Carmustine - therapeutic use Combined Modality Therapy Cytarabine - adverse effects Cytarabine - therapeutic use Etoposide - adverse effects Etoposide - therapeutic use Female Humans lymphoma Lymphoma - mortality Lymphoma - therapy Male Melphalan - adverse effects Melphalan - therapeutic use Middle Aged Survival Rate Transplantation, Autologous |
| title | BEAM Autografting in Lymphoma-Experience at One Centre |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-19T14%3A13%3A04IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-informahealthcare_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=BEAM%20Autografting%20in%20Lymphoma-Experience%20at%20One%20Centre&rft.jtitle=Leukemia%20&%20lymphoma&rft.au=Smith,%20Adrian%20G.&rft.date=1992&rft.volume=7&rft.issue=S1&rft.spage=23&rft.epage=28&rft.pages=23-28&rft.issn=1042-8194&rft.eissn=1029-2403&rft_id=info:doi/10.3109/10428199209061560&rft_dat=%3Cinformahealthcare_cross%3E10_3109_10428199209061560%3C/informahealthcare_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/1493455&rfr_iscdi=true |